Literature DB >> 16640958

Field of confusion: future prospects for fibrate therapy in cardiovascular disease.

Robert S Rosenson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16640958     DOI： 10.1007/s11883-006-0076-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  16 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

Authors:  S M Haffner; C M Alexander; T J Cook; S J Boccuzzi; T A Musliner; T R Pedersen; J Kjekshus; K Pyörälä
Journal:  Arch Intern Med       Date:  1999 Dec 13-27

3.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

Review 4.  New approaches in the intensive management of cardiovascular risk in the metabolic syndrome.

Authors:  Robert S Rosenson
Journal:  Curr Probl Cardiol       Date:  2005-05       Impact factor: 5.200

5.  Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

Authors:  Hanna Bloomfield Rubins; Sander J Robins; Dorothea Collins; David B Nelson; Marshall B Elam; Ernst J Schaefer; Fred H Faas; James W Anderson
Journal:  Arch Intern Med       Date:  2002 Dec 9-23

6.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

Authors: 
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

7.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

Review 8.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

9.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

10.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

Authors:  Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood
Journal:  Eur Heart J       Date:  2003-09       Impact factor: 29.983
View more
  3 in total

Review 1.  Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.

Authors:  Kwang Kon Koh; Michael J Quon; Robert S Rosenson; Wook-Jin Chung; Seung Hwan Han
Journal:  Int J Cardiol       Date:  2007-07-20       Impact factor: 4.164

Review 2.  Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction.

Authors:  Kwang Kon Koh; Seung Hwan Han; Pyung Chun Oh; Eak Kyun Shin; Michael J Quon
Journal:  Atherosclerosis       Date:  2009-09-12       Impact factor: 5.162

Review 3.  Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.

Authors:  Robert S Rosenson; R Scott Wright; Michael Farkouh; Jorge Plutzky
Journal:  Am Heart J       Date:  2012-10-16       Impact factor: 4.749
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.